Iloprost

伊洛前列素

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameIloprost
Drug Alias NameIloderm伊洛前列环素IlocitIloprost inhalation solutionIloprost power 15 +[19
ClassificationSmall molecules
Mechanisms of ActionProstanoid receptor agonists
TargetsProstanoid receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Humeral FracturesScleroderma, Systemic +[21
Global Approved IndicationsPulmonary Arterial HypertensionHypertension, Pulmonary
Approved Indications in ChinaPulmonary Arterial Hypertension
Original Approved Country/TerritoryEU
Original Approved Date2003/09/15
Country/TerritoryBelgiumUnited StatesPoland +[15
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesActelion Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active IndicationsCoronavirus Disease 2019 (COVID-19)Humeral FracturesAnemia, Sickle Cell +[9
Inactive IndicationsScleroderma, SystemicRaynaud DiseaseMyocardial Infarction +[12

Other Information

ATC CodeB01AC11